SZLMY vs RPRX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SZLMY · SWISS LIFE HOLDING AG UNSP ADR EACH REPR 1/20 ORD$59.52 ▼ 1.31%
RPRX · Royalty Pharma$67.30 ▼ 0.40%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SZLMY +12.8%
- RPRX +78.0%
Head to head
| Metric | SZLMY | RPRX |
|---|---|---|
| Price | $59.52 | $67.30 |
| Change today | ▼ 1.31% | ▼ 0.40% |
| Market cap | $29.97B | $29.97B |
| Return, 3 months | +1.2% | +16.6% |
| Return, year to date | +7.1% | +76.6% |
| Return, 1 year | +13.7% | +77.9% |
| P/E (TTM) | 20.6 | 44.0 |
| P/B | 4.3 | 4.4 |
| P/E percentile vs own 5y | – | 84th |
| Dividend yield | 3.91% | 1.37% |
| Revenue growth (YoY, latest qtr) | – | +16.5% |
| Net profit growth (YoY) | – | -12.0% |
| Gross margin | – | – |
| Operating margin | – | 62.3% |
| Net margin | – | 32.0% |
| Return on equity | – | 12.3% |
| Analyst target vs. price | – | +5.0% |
| Analyst buy share | – | 100% |
| RSI (14) | 64 | 72 |
| 30-day volatility | 19.1% | 23.1% |
| Max drawdown, 1 year | -13.4% | -12.1% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SZLMY is the largest of the group by market value.
- RPRX has returned the most over the past year.
- SZLMY carries the lowest trailing P/E.
- SZLMY pays the highest dividend yield.
- SZLMY has been the calmest stock over the last 30 days.